EA201791286A1 - Схема дозирования для селективного агониста рецептора s1p - Google Patents

Схема дозирования для селективного агониста рецептора s1p

Info

Publication number
EA201791286A1
EA201791286A1 EA201791286A EA201791286A EA201791286A1 EA 201791286 A1 EA201791286 A1 EA 201791286A1 EA 201791286 A EA201791286 A EA 201791286A EA 201791286 A EA201791286 A EA 201791286A EA 201791286 A1 EA201791286 A1 EA 201791286A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
dosing scheme
selective agonist
dosing
scheme
Prior art date
Application number
EA201791286A
Other languages
English (en)
Other versions
EA036075B1 (ru
Inventor
Джаспер Динджеманс
Маттиас Хох
Андреас Краузе
Original Assignee
Актелион Фармасьютиклз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54843844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791286(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Актелион Фармасьютиклз Лтд. filed Critical Актелион Фармасьютиклз Лтд.
Publication of EA201791286A1 publication Critical patent/EA201791286A1/ru
Publication of EA036075B1 publication Critical patent/EA036075B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)

Abstract

Данное изобретение относится к схеме дозирования для (R)-5-[3-хлоро-4-(2,3-гидроксипропокси)бенз[Z]илиден]-2-([Z]-пропилимино)-3-о-толилтиазолидин-4-она.
EA201791286A 2014-12-11 2015-12-10 Схема дозирования для селективного агониста рецептора s1p1 EA036075B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2014077469 2014-12-11
EP2015058202 2015-04-15
PCT/EP2015/079208 WO2016091996A1 (en) 2014-12-11 2015-12-10 Dosing regimen for a selective s1p1 receptor agonist

Publications (2)

Publication Number Publication Date
EA201791286A1 true EA201791286A1 (ru) 2017-12-29
EA036075B1 EA036075B1 (ru) 2020-09-23

Family

ID=54843844

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791286A EA036075B1 (ru) 2014-12-11 2015-12-10 Схема дозирования для селективного агониста рецептора s1p1

Country Status (31)

Country Link
US (4) US10220023B2 (ru)
EP (2) EP3256125B1 (ru)
JP (1) JP6244497B1 (ru)
KR (4) KR20200013086A (ru)
CN (2) CN117137912A (ru)
AU (2) AU2015359346B2 (ru)
CA (1) CA2968180C (ru)
CL (1) CL2017001457A1 (ru)
CY (1) CY1125170T1 (ru)
DK (1) DK3256125T3 (ru)
EA (1) EA036075B1 (ru)
ES (1) ES2909071T3 (ru)
FR (1) FR22C1021I2 (ru)
HR (1) HRP20220359T8 (ru)
HU (2) HUE057865T2 (ru)
IL (1) IL252727B (ru)
LT (2) LT3256125T (ru)
MX (2) MX2020011182A (ru)
MY (1) MY188764A (ru)
NL (1) NL301174I2 (ru)
NO (1) NO2022023I1 (ru)
PH (1) PH12017501059A1 (ru)
PL (1) PL3256125T3 (ru)
PT (1) PT3256125T (ru)
RS (1) RS63048B1 (ru)
SG (1) SG11201704563RA (ru)
SI (1) SI3256125T1 (ru)
TW (1) TW201625242A (ru)
UA (1) UA122064C2 (ru)
WO (1) WO2016091996A1 (ru)
ZA (1) ZA201704624B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
EP3256125B1 (en) 2014-12-11 2022-01-26 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
MX2022000835A (es) 2019-07-22 2022-02-10 Actelion Pharmaceuticals Ltd Metodos para tratar la esclerosis multiple.
CN114599363A (zh) 2019-10-31 2022-06-07 爱杜西亚药品有限公司 Cxcr7拮抗剂与s1p1受体调节剂的组合
MX2022010962A (es) 2020-03-06 2022-10-07 Actelion Pharmaceuticals Ltd Metodos para ralentizar la perdida de volumen cerebral.
KR20230156952A (ko) 2021-03-17 2023-11-15 액테리온 파마슈티칼 리미티드 약제 투여 시스템
CA3220723A1 (en) 2021-10-11 2023-04-20 Allitia DIBERNARDO Methods of treating multiple sclerosis
CA3220715A1 (en) 2021-10-11 2023-04-20 Krista Spiller Methods of treating multiple sclerosis
US20230114486A1 (en) 2021-10-11 2023-04-13 Actelion Pharmaceuticals Ltd Methods Of Treating Multiple Sclerosis
EP4415699A1 (en) 2021-10-11 2024-08-21 Laboratoires Juvise Pharmaceuticals Methods of treating multiple sclerosis
TW202333688A (zh) 2021-11-05 2023-09-01 瑞士商艾克泰聯製藥有限公司 治療多發性硬化症之方法
US20240261268A1 (en) 2022-02-11 2024-08-08 Vanda Pharmaceuticals Inc. Methods of slowing an increase in brain ventricular volume

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
PL1689726T3 (pl) 2003-11-21 2011-05-31 Actelion Pharmaceuticals Ltd Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne
MX2007006373A (es) 2004-11-29 2007-06-20 Novartis Ag Regimen de dosificacion de un agonista del receptor s1p.
US7879821B2 (en) 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
EP2094676B1 (en) 2006-11-23 2013-04-10 Actelion Pharmaceuticals Ltd. New process for the preparation of 2-iminothiazolidin-4-one derivatives
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
SG171888A1 (en) 2008-12-22 2011-07-28 Novartis Ag Dosage regimen of an s1p receptor agonist
HUE026869T2 (en) 2008-12-22 2016-08-29 Novartis Ag Dosing regimen for fingolimod for the treatment of multiple sclerosis
MX350891B (es) 2012-08-17 2017-09-22 Actelion Pharmaceuticals Ltd Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso.
EP3256125B1 (en) 2014-12-11 2022-01-26 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1

Also Published As

Publication number Publication date
WO2016091996A1 (en) 2016-06-16
EP4056179A1 (en) 2022-09-14
KR20210126792A (ko) 2021-10-20
US10857134B2 (en) 2020-12-08
IL252727A0 (en) 2017-08-31
MY188764A (en) 2021-12-30
CN117137912A (zh) 2023-12-01
DK3256125T3 (da) 2022-03-21
NZ733463A (en) 2023-10-27
NZ768672A (en) 2023-10-27
US20190151292A1 (en) 2019-05-23
KR102427123B1 (ko) 2022-07-28
US11771683B2 (en) 2023-10-03
CN106999461A (zh) 2017-08-01
EP3256125B1 (en) 2022-01-26
HUS2200021I1 (hu) 2022-05-28
PL3256125T3 (pl) 2022-05-09
ZA201704624B (en) 2022-03-30
CL2017001457A1 (es) 2018-02-09
JP6244497B1 (ja) 2017-12-06
PH12017501059A1 (en) 2017-11-27
CY1125170T1 (el) 2022-07-22
NL301174I1 (ru) 2022-05-09
JP2017538706A (ja) 2017-12-28
MX2020011182A (es) 2022-10-03
KR102590068B1 (ko) 2023-10-16
CA2968180C (en) 2020-01-28
CA2968180A1 (en) 2016-06-16
AU2020202684A1 (en) 2020-05-14
HRP20220359T8 (hr) 2022-05-27
EP3256125A1 (en) 2017-12-20
AU2015359346B2 (en) 2020-05-07
NO2022023I1 (no) 2022-06-10
RS63048B1 (sr) 2022-04-29
AU2015359346A8 (en) 2017-08-03
UA122064C2 (uk) 2020-09-10
FR22C1021I2 (fr) 2023-04-14
KR20200013086A (ko) 2020-02-05
FR22C1021I1 (fr) 2022-07-15
SI3256125T1 (sl) 2022-04-29
IL252727B (en) 2021-02-28
TW201625242A (zh) 2016-07-16
KR20230147768A (ko) 2023-10-23
LTPA2022505I1 (ru) 2022-06-10
AU2015359346A1 (en) 2017-07-27
PT3256125T (pt) 2022-05-06
MX2017007638A (es) 2017-09-11
SG11201704563RA (en) 2017-07-28
EA036075B1 (ru) 2020-09-23
ES2909071T3 (es) 2022-05-05
US20170319555A1 (en) 2017-11-09
HRP20220359T1 (hr) 2022-05-13
HUE057865T2 (hu) 2022-06-28
US10220023B2 (en) 2019-03-05
LT3256125T (lt) 2022-04-11
US20180147188A9 (en) 2018-05-31
KR20170094335A (ko) 2017-08-17
US20210052555A1 (en) 2021-02-25
NL301174I2 (nl) 2022-06-09
US20230131600A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
EA201791286A1 (ru) Схема дозирования для селективного агониста рецептора s1p
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
DK3283110T3 (da) Antistoffer rettet mod interleukin-36-receptor (il-36r)
DK3368060T3 (da) Glugacon-receptor-agonister
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
CY2022011I2 (el) Δοσολογικο σχημα για την πονεσιμοδη, εναν επιλεκτικο αγωνιστη του υποδοχεα s1p1
DK3180329T3 (da) Triazoler som nr2b receptorinhibitorer
CL2016002562A1 (es) Régimen de dosificación de liberación inmediata de moduladores s1p.
HK1257166A1 (zh) 作為大麻素受體2激動劑的苯基衍生物
DK3265459T3 (da) Amidforbindelser som 5-ht4-receptoragonister
IL252882B (en) History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists
MA40858A (fr) Composés antagonistes des récepteurs d3 à la dopamine
EP3463413A4 (en) PARTIAL INSULIN RECEPTOR AGONISTS
EP3098414A4 (en) Muffler for construction machine
DK3568675T3 (da) Fødesnegl til kombinationsvægt
DK3250549T3 (da) Cyclopropylmethanaminer som selektive 5-HT(2C)-receptoragonister
IT201700098380U1 (it) Imboccatura per cavalli
IT201700043199U1 (it) Calzatura per cavalli
IT201700029084A1 (it) Macchina per ingabbiare avicoli
DK3298887T3 (da) Fremgangsmåde til at fodre nyttedyr
TH1601000316A (th) อะโกนิสต์ของตัวรับวาโซเพรสซิน-2
BR112017001498A2 (pt) receptores de antígeno quiméricos bcma
TH1601000381A (th) สารประกอบอินโดไลซีนแบบใหม่, กระบวนการในการเตรียมสารประกอบดังกล่าว และองค์ประกอบทางเภสัชกรรมที่ประกอบด้วยสารประกอบดังกล่าว
TH1601003483A (th) สารประกอบอินดาโซลในฐานะอะกอนิสต์ของ 5-ht4 รีเซปเตอร์